Bausch & Lomb saves 2022's medtech IPO scene from washout as markets close for new entrants.
2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.
Few developers are feeling bold enough to brave the markets, though the bigger deals are finding some support.
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
The sector must hope that the bottom has been reached.
A correction – as long as it is not too severe – might not be a bad thing for the sector.
Medtechs rushed for the markets last year, but had an uneasy time once there.
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.